Rheumatoid Arthritis (RA) - Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026

Rheumatoid Arthritis (RA) Emerging Therapy and TPP Insights

Thelansis's "Rheumatoid Arthritis (RA) Emerging Therapy, with Unmet Needs and TPP Insights Report - 2026" provides a comprehensive analysis of the emerging competitive landscape, unmet needs, target product profiles (TPPs), trial designs, and KOL insights on key emerging therapies and key drug development opportunities in the indication.

Rheumatoid Arthritis Overview

Rheumatoid arthritis (RA) is a chronic, systemic autoimmune disorder characterized by persistent inflammation of the synovial membrane, leading to progressive joint destruction, pain, stiffness, swelling, and irreversible functional disability. The disease extends beyond joints, frequently manifesting with systemic complications such as cardiovascular disease, interstitial lung disease, osteoporosis, and chronic fatigue, significantly increasing morbidity and mortality risk.

At moderate to severe stages, patients experience substantial impairment in daily functioning and quality of life, with disease activity assessed using composite indices (e.g., DAS28, CDAI) and supported by serological biomarkers such as rheumatoid factor (RF) and anti-cyclic citrullinated peptide (anti-CCP) antibodies. Disease progression is driven by complex immune dysregulation involving pro-inflammatory cytokines, particularly TNF-a, IL-6, and JAK-STAT signaling pathways.

Management is centered on a treat-to-target (T2T) approach, emphasizing early, aggressive intervention to achieve sustained remission or low disease activity. Conventional synthetic DMARDs, particularly methotrexate, remain the backbone of therapy and are frequently combined with biologic DMARDs (e.g., TNF inhibitors, IL-6 receptor antagonists) or targeted synthetic agents such as JAK inhibitors for patients with inadequate response. Corticosteroids and NSAIDs are used adjunctively for rapid symptom control but are not suitable for long-term disease modification.

Despite significant therapeutic advancements, a considerable proportion of patients exhibit primary or secondary treatment failure, persistent disease activity, or intolerance to therapies, necessitating multiple treatment switches. Additionally, long-term safety concerns, high treatment costs, and heterogeneity in treatment response continue to pose challenges in optimal disease management.

The evolving treatment landscape is increasingly focused on precision medicine, incorporating biomarker-driven patient stratification, novel immune targets, and optimized sequencing strategies to improve durability of response. Future innovation aims to address refractory disease, minimize systemic complications, and ultimately achieve sustained remission with improved safety and patient-centric outcomes..

Key Highlights

• In Germany, prevalence is expected to grow from 1,046,761 to 1,122,386, indicating a consistently large patient pool.
• In France, prevalent moderate to severe RA cases are projected to increase from 309,511 to 331,872, reflecting a steady rise in disease burden.
• Moderate to severe RA continues to drive significant disability due to progressive joint damage and systemic complications.
• Despite availability of advanced biologics and targeted therapies, treatment resistance and disease flares remain common.
• Increasing focus on personalized medicine and biomarker-driven treatment selection to improve long-term outcomes.

Market Overview

• The Germany RA market is expected to increase from $3,153M to $3,554M, driven by a large patient base and high biologic adoption.
• The Spain moderate to severe RA market is projected to grow from $770M to $838M, reflecting moderate expansion.
• Market growth is supported by:
• Increased uptake of biologics and JAK inhibitors
• Longer treatment duration in chronic disease management
• Despite stable-to-moderate patient growth, market value is driven by premium therapies and combination treatment approaches.
• Future growth will depend on next-generation targeted therapies and improved disease-modifying strategies.

Insights driven by surveys* with physician / key opinion leaders:

• Survey findings are corroborated and enriched by insights from interviews with leading KOLs
• Survey is customized based on client requirements

Deliverables format:

• PowerPoint presentation
• MS Excel

Key business questions answered:

• Detailed emerging competitive landscape
• Pipeline analysis
• Target patients for emerging therapies
• Key companies
• Key mechanism of actions
• Launch date estimates, etc.
• Clinical trial landscape analysis
• Target patient segments
• Trial endpoints
• Trial design
• Recruitment criteria, etc.
• Unmet Needs and Opportunities
• Performance of key current therapies
• Top areas of unmet needs
• Opportunity sizing for key unmet needs
• Target Product Profiles
• Attributes and levels
• Physician likelihood of prescribing
• Expected patient shares
• KOL insights on key emerging therapies
• Level of awareness
• Expected use / line of therapy
• Extent to fulfil key unmet needs
• KOL quotes

Countries Covered

• G8
  • United States
  • EU5
    • France
    • Germany
    • Italy
    • Spain
    • U.K.
  • Japan
  • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

• Kali Therapeutics, Inc.
• Surf Therapeutics
• Philogen S.p.A.
• Qilu Pharmaceutical Co., Ltd.
• Toll Biotech Co. Ltd. (Beijing)
• Shanghai Kanda Biotechnology Co., Ltd.
• Kashiv BioSciences, LLC
• Lynk Pharmaceuticals Co., Ltd
• Eli Lilly and Company
• Merck Sharp & Dohme LLC
• Novartis Pharmaceuticals
• AstraZeneca
• Bristol-Myers Squibb
• Changchun GeneScience Pharmaceutical Co., Ltd.
• Shenzhen MagicRNA Biotechnology Co., Ltd
• AbbVie
• Sanofi
• Lifordi Immunotherapeutics, Inc.
• Capstan Therapeutics
• Seismic Therapeutic AU Pty Ltd